Dec'19 Actual | Dec'20 Actual | Dec'21 Actual | Dec'22 Actual | Dec'23 Actual | Dec'24 Estimate | Dec'25 Estimate | Dec'26 Estimate | Dec'27 Estimate | Dec'28 Estimate | Dec'29 Estimate | Dec'30 Estimate | Dec'31 Estimate | Dec'32 Estimate | Dec'33 Estimate | Dec'34 Terminal | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 136.5 1,287.6% | 164.4 20.5% | 188.5 14.6% | 245.4 30.2% | 305.2 24.4% | 357.9 17.3% | 509.5 42.4% | 1,014.7 99.1% | 1,857.1 83.0% | 2,763.0 48.8% | 3,900.2 41.2% | 5,207.6 33.5% | 6,556.1 25.9% | 7,753.3 18.3% | 8,577.6 10.6% | 8,834.9 3.0% |
% margin | (235.2) (172.4%) | (265.2) (161.3%) | (367.8) (195.1%) | (478.1) (194.9%) | (709.6) (232.5%) | (357.9) (100.0%) | (509.5) (100.0%) | (1,014.7) (100.0%) | (1,857.1) (100.0%) | (2,763.0) (100.0%) | (3,900.2) (100.0%) | (5,207.6) (100.0%) | (6,556.1) (100.0%) | (7,753.3) (100.0%) | (8,577.6) (100.0%) | (8,834.9) (100.0%) |
NOPAT % effective tax rate | (236.0) (172.9%) | (266.5) (162.1%) | (366.3) (194.4%) | (479.5) (195.4%) | (712.1) (233.3%) | (359.1) (100.3%) | (511.3) (100.3%) | (1,018.1) (100.3%) | (1,863.4) (100.3%) | (2,772.5) (100.3%) | (3,913.5) (100.3%) | (5,225.5) (100.3%) | (6,578.5) (100.3%) | (7,779.8) (100.3%) | (8,606.9) (100.3%) | (8,865.1) (100.3%) |
% of revenue | 10.2 7.5% | 20.1 12.2% | 27.8 14.8% | 24.3 9.9% | 10.6 3.5% | 33.6 9.4% | 47.8 9.4% | 95.2 9.4% | 174.2 9.4% | 259.1 9.4% | 365.8 9.4% | 488.4 9.4% | 614.8 9.4% | 727.1 9.4% | 804.4 9.4% | 828.5 9.4% |
% of revenue | (42.3) (31.0%) | (6.8) (4.1%) | (7.3) (3.9%) | (9.9) (4.0%) | (13.3) (4.4%) | (14.6) (4.1%) | (20.8) (4.1%) | (41.4) (4.1%) | (75.8) (4.1%) | (112.8) (4.1%) | (159.2) (4.1%) | (212.6) (4.1%) | (267.6) (4.1%) | (316.5) (4.1%) | (350.2) (4.1%) | (360.7) (4.1%) |
% of revenue | (63.0) (46.1%) | (3.0) (1.8%) | (58.6) (31.1%) | 6.6 2.7% | (39.2) (12.8%) | (49.2) (13.8%) | (70.1) (13.8%) | (139.5) (13.8%) | (255.4) (13.8%) | (379.9) (13.8%) | (536.3) (13.8%) | (716.1) (13.8%) | (901.5) (13.8%) | (1,066.2) (13.8%) | (1,179.5) (13.8%) | (1,214.9) (13.8%) |
Free Cash Flow to Firm (FCFF) % of revenue | (331.0) (242.6%) | (256.2) (155.8%) | (404.3) (214.5%) | (458.5) (186.9%) | (754.0) (247.0%) | (389.4) (108.8%) | (554.3) (108.8%) | (1,103.9) (108.8%) | (2,020.4) (108.8%) | (3,006.1) (108.8%) | (4,243.3) (108.8%) | (5,665.8) (108.8%) | (7,132.8) (108.8%) | (8,435.4) (108.8%) | (9,332.2) (108.8%) | (9,612.2) (108.8%) |
% of FCFF used in calculation | 100.0% | 86.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | ||||||
Discount period | 0.50 | 1.50 | 2.50 | 3.50 | 4.50 | 5.50 | 6.50 | 7.50 | 8.50 | |||||||
Discount factor | 0.96 | 0.87 | 0.80 | 0.73 | 0.67 | 0.61 | 0.56 | 0.51 | 0.46 | |||||||
Discounted FCFF (DFCFF) |
Discover the top 20 best undervalued stocks to buy for Feb 2025, listed on the Nasdaq or NYSE.
Explore the best low P/E stocks to buy in 2025, featuring top companies trading at low P/E ratios.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Feb 2025.
As of Feb 20, 2025, Insmed Incorporated's Discounted Cash Flow (DCF) valuation estimates its share price at N/A. This suggests it may be overvalued by (100.0%) compared to its current price of around $83.6, using a WACC of 9.5% and growth rates of 3.0%.
As of Feb 20, 2025, Insmed Incorporated's Weighted Average Cost of Capital (WACC) is approximately 9.5%.
As of Feb 20, 2025, Insmed Incorporated's Enterprise Value (EV) is approximately $0.0. This value reflects the company's total market capitalization plus debt, minus cash and cash equivalents, providing a comprehensive measure of its overall value in the market.